Archive for the ‘Diabetes’ Category

May 1, 2010

Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy

House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD.   JAMA.   2010 Apr 28;303(16):1603-9

This RCT examined compared a strategy of homocysteine reduction using folic acid, vitamin B6, and vitamin B12 versus placebo in patient with diabetic nephropathy. The active therapy arm experienced a greater decrease in GFR and an increase in vascular events.

  • Share/Bookmark
1 Comment Posted in Chronic Kidney Disease, Diabetes
May 1, 2010

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.   N Engl J Med.   2010 Apr 22;362(16):1477-90

9306 patients with IGTT and established cardiovascular disease or cardiovascular risk factors were randomized to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. After a median 5 year follow-up, there was a relative reduction of 14% in the incidence of diabetes in the valsartan group. [...]

  • Share/Bookmark
1 Comment Posted in Diabetes, RAS Blockade
March 23, 2010

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.   N Engl J Med.   2010 Apr 22;362(16):1477-90

This RCT randomized patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo in addition to lifestyle modification. No reduction in cardiovascular events was noted at 5 years, but the incidence of diabetes was reduced; 33.1% in the valsartan group vs 36.8% [...]

  • Share/Bookmark
No Comments Posted in Diabetes, RAS Blockade
March 23, 2010

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F.   N Engl J Med.   2010 Apr 29;362(17):1575-85

In the ACCORD BP study, patients with type 2 diabetes at high risk for cardiovascular events were randomized to a target systolic blood pressure of <120 mmHg vs <140 mmHg. After 4.7 years, there was no significant difference in cardiovascular events or mortality but there was an increase in serious adverse events related to anti-hypertensive [...]

  • Share/Bookmark
1 Comment Posted in Diabetes, Hypertension
March 1, 2009

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.   Clin J Am Soc Nephrol.   2009 Feb;4(2):361-8

  • Share/Bookmark
No Comments Posted in Diabetes
March 1, 2009

Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A, SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators.   J Am Soc Nephrol.   2009 Mar;20(3):655-64

  • Share/Bookmark
No Comments Posted in Diabetes
September 1, 2008

The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysis.

McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G.   Am J Kidney Dis.   2008 Sep;52(3):454-63

  • Share/Bookmark
No Comments Posted in Diabetes
May 1, 2008

Effect of a multifactorial intervention on mortality in type 2 diabetes.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O.   N Engl J Med.   2008 Feb 7;358(6):580-91

  • Share/Bookmark
No Comments Posted in Diabetes
February 1, 2008

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C.   Lancet.   2008 Jan 12;371(9607):117-25

  • Share/Bookmark
No Comments Posted in Diabetes
January 1, 2008

Kidney disease in diabetology: lessons from 2008.

.   .   

  • Share/Bookmark
No Comments Posted in Diabetes
December 1, 2007

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

.   .   

  • Share/Bookmark
No Comments Posted in Diabetes
November 1, 2007

Management of Glycemia in Patients With Diabetes Mellitus and CKD.

.   .   

  • Share/Bookmark
No Comments Posted in Diabetes
October 1, 2007

Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.

.   .   

  • Share/Bookmark
No Comments Posted in Diabetes
Get Adobe Flash playerPlugin by wpburn.com wordpress themes